Enhancing Patient Care with Simplified and Precise Dosing

Flexilev^® in OraFID^® offers a unique treatment option for ensuring symptom control in Parkinson’s Disease.¹

As Parkinson’s disease progresses, patients frequently experience variations in their motor abilities throughout the day. Treatment during this phase of the disease can be challenging and often require careful optimization of levodopa intake to maintain optimal symptom control and avoid occasional treatment failures such as dose gaps*. Flexilev in OraFID provides an innovative solution for fine-tuning levodopa treatment, helping to maintain consistent symptom control and improve patients quality of life.

Flexilev consist of water soluble minitablets containing levodopa/carbidopa (5 mg/1.25 mg). This formulation allows for exact dosing in increments of 5 mg, enabling improved symptom control by minimizing fluctuations of levodopa in plasma.²

OraFID is an innovative user-friendly mechanical dispenser, pre-filled with 2 250 minitablets, ready for use. This combination of drug and device facilitates practical handling of advanced dosing schedules, to address each patient’s specific requirements at any given time.

The Flexilev in OraFID drug/device combination minimizes the risk of under- or overdosing and associated side effects*. It offers a simplified approach to achieving precise medication delivery and continuous dopaminergic stimulation.

Learn more about the OraFID dispenser here: www.orafid.com

*Underdosing or shortened time span of levodopa efficacy after each dose (dose gaps) can lead to stiffness (bradykinesia/rigidity), so-called “off” episodes, while overdosing may cause excessive movements/dyskinesia.

ABOUT PARKINSON DISEASE
Parkinson disease is a degenerative condition of the brain associated with motor symptoms (slow movement, tremor, rigidity and imbalance) and other complications including cognitive impairment, mental health disorders, sleep disorders, pain and sensory disturbances.²
Parkinson’s disease affects 1-2 per 1 000 of the population at any time. PD prevalence is increasing with age, and PD affects 1% of the population above 60 years.¹

Navamedic markets Flexilev in OraFID in Sweden, Norway and Denmark and has outlicensed marketing in FI, NL, BE, LUX, UK, PL, AT to Orion OY.

References:
1. Johansson et al. Individualization of levodopa treatment using a microtablet dispenser and ambulatory accelerometry. Eur CNS Neurosci Ther. 2018 May;24(5):439-447. doi: 10.1111/cns.12807. Epub 2018 Jan 25.
2. SPC Felleskatalogen (https://www.felleskatalogen.no/medisin/flexilev-navamedic-645989)
3. Epidemiology of Parkinson’s disease (https://pubmed.ncbi.nlm.nih.gov/28150045/)